Incyte Corporation — FY2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018; filed February 14, 2019. Although the request references 2018 Q4, this is an annual report. Amounts below are in U.S. dollars unless noted.
Business context
Incyte is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics. Its principal marketed products were JAKAFI in the United States and ICLUSIG in Europe and certain other markets. It also earns royalties and milestone payments through collaborations, including with Novartis and Lilly. The company reported one operating segment.
Key financial metrics
| Metric | FY2018 | FY2017 | Change / context |
|---|---|---|---|
| Total revenue | $1,881.9 million | $1,536.2 million | Up 22.5% |
| Product revenue, net | $1,466.9 million | $1,200.3 million | Up 22.2% |
| JAKAFI revenue | $1,387.0 million | $1,133.4 million | Up 22.4%; increase reflected volume and price |
| ICLUSIG revenue | $79.9 million | $66.9 million | Up 19.4% |
| Product royalties | $234.8 million | $160.8 million | Up 46.0%; JAKAVI $194.7 million and OLUMIANT $40.1 million in 2018 |
| Milestone and contract revenue | $180.0 million | $175.0 million | Primarily Lilly and Novartis milestones |
| Research and development | $1,198.0 million | $1,326.1 million | Down 9.7%, mainly reflecting fewer collaboration upfront and milestone charges |
| Selling, general and administrative | $434.4 million | $366.3 million | Up 18.6%, including commercialization and patient-assistance-related spending |
| Operating income (loss) | $129.2 million | $(243.4) million | Operating margin approximately 6.9%, versus a loss margin of approximately 15.8% |
| Net income (loss) | $109.5 million; $0.51 diluted EPS | $(313.1) million; $(1.53) diluted EPS | Returned to annual profitability |
| Operating cash flow | $336.2 million | $(93.0) million | Improved with revenue growth, lower collaboration payments and working-capital changes |
| Cash, equivalents and marketable securities | $1,438.3 million | $1,169.6 million | Working capital was $1,407.0 million at year-end |
| Convertible senior notes | $17.4 million carrying value | $24.0 million | $19.1 million principal due in 2020; no current portion at year-end 2018 |
Cost of product revenues was $94.1 million, including $63.0 million of U.S. JAKAFI royalties payable to Novartis and $21.5 million of ICLUSIG intangible amortization. The filing does not provide a consolidated gross-margin measure that isolates product economics from collaboration revenue and operating expenses.
For Q4 2018, revenue was $528.4 million and net income was $69.1 million, compared with revenue of $444.2 million and a net loss of $149.6 million in Q4 2017. Diluted EPS was $0.32 versus a loss of $0.71.
Material changes and notable developments
- Revenue growth was led by JAKAFI sales and rising JAKAVI and OLUMIANT royalties. Novartis milestones included $60 million after annual sales of a licensed JAK product reached $900 million; Lilly milestones included $100 million following FDA approval of OLUMIANT’s 2 mg rheumatoid-arthritis dose and $20 million for first patient treatment in its lupus Phase III program.
- The 2018 profit turnaround followed a 2017 loss that included substantial collaboration charges and $54.9 million of senior-note conversion expense. Research and development expense remained high despite declining year over year.
- Operating cash flow swung positive. Investing cash use fell to $86.4 million from $350.0 million, while financing cash flow was $14.7 million versus $690.2 million in 2017, when a public offering generated $649.4 million net proceeds.
- Unrealized losses on long-term investments were $44.1 million in 2018, principally involving Agenus, Merus, Calithera and Syros. The fair value of acquisition-related contingent consideration tied to ICLUSIG was $287.0 million at year-end; it is a liability, not reported debt.
- Capital spending was $73.5 million. The company was developing a new European headquarters in Morges and a large-molecule production facility in Switzerland, both expected to be completed in 2020.
Outlook, risks and contingencies
- No specific revenue, earnings or cash-flow guidance is provided. Management stated that operating cash flow and available cash, cash equivalents and marketable securities should meet capital needs for the foreseeable future, while noting that needs depend on development, commercialization, facilities and strategic transactions.
- Pipeline developments reported around the filing date included FDA Priority Review of the ruxolitinib GVHD application, with the review period extended by three months in February 2019; FDA Breakthrough Therapy designation for pemigatinib in previously treated FGFR2-translocated cholangiocarcinoma; and Lilly’s announcement that baricitinib met primary endpoints in two Phase III atopic-dermatitis trials. Novartis expected to submit a capmatinib application for NSCLC with MET exon 14 skipping mutations in 2019.
- Key business risks include reliance on JAKAFI for a substantial share of revenue; competition, including potential generic JAKAFI entry; pricing and reimbursement pressure; clinical-trial and regulatory uncertainty; and dependence on third-party manufacturers and collaborators.
- In February 2016, Incyte received notice of an ANDA seeking approval for generic JAKAFI and challenging certain patents. The company said the FDA had taken no action on the ANDA as of the report; patent litigation and exclusivity remain material risks.
- In December 2018, the U.S. Department of Justice issued a civil investigative demand concerning speaker programs and patient-assistance programs, including support for nonprofit organizations. Incyte was cooperating, had not been informed of the substance of any civil claims, could not estimate a possible loss, and recorded no reserve.
- Other potential exposures include product liability, regulatory compliance, foreign-exchange movements, investment-value volatility and execution risk on facility projects. The company relied on third parties for manufacturing and cited potential supply-chain vulnerability, including Chinese-sourced raw materials for ruxolitinib.
Important facts for investors to verify
- Whether JAKAFI sales and royalty growth can continue, and the effect of price increases, rebates and government chargebacks on net revenue.
- The status and potential timing of the generic JAKAFI challenge, relevant patent protection and the commercial impact of new competitors.
- Progress, regulatory outcomes and commercial potential for ruxolitinib in GVHD, pemigatinib, itacitinib, parsaclisib and other pipeline programs.
- The outcome and any financial or compliance consequences of the DOJ inquiry; no loss estimate or reserve was provided.
- Cash generation against ongoing R&D, collaboration commitments, the $287.0 million contingent-consideration liability and planned facility investment.
- The company reported an unqualified audit opinion and effective internal control over financial reporting as of December 31, 2018.